The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction Act. | The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction Act.

The blockbuster diabetes and weight-loss drug semaglutide (Ozempic, Rybelsus, Wegovy) along with therapies for asthma, cancers, and various other conditions were among the 15 drugs the Biden administration selected for the next round of Medicare price negotiation.

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs for mandatory price negotiations.

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy.Here's

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before President-elect Donald Trump takes office.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.